TriangleFOR PATIENTS · SOURCE READING
CNS Lesions
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment of Low-Risk LCH in Children
Treatment of newly diagnosed childhood LCH central nervous system (CNS) lesions may include:
Source links and citations
Chemotherapy with or without steroid therapy.
Source links and citations
Treatment of newly diagnosed LCH CNS neurodegenerative syndrome may include:
Source links and citations
Targeted therapy with BRAF inhibitors (vemurafenib or dabrafenib).
Source links and citations
Chemotherapy.
Targeted therapy with a monoclonal antibody (rituximab).
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice